Leveraging advanced spatial proteomics, scientists have identified the JAK/STAT pathway as a critical target for treating toxic epidermal necrolysis, offering new hope for patients with this life-threatening skin disease. Disease course in a patient with TEN (SCORTEN 4) associated with cancer treatment. Disease progression was observed during high-dose intravenous methylprednisolone treatment and the patient developed persistent hyperglycaemia.
JAK1i rescue therapy with abrocitinib was initiated on day 4, resulting in visible cessation of progression within 48 h and initial re-epithelialization within 4 days. Top, photographs of the back of the patient, showing the degree of re-epithelialization at the indicated timepoints after hospital admission. Bottom, Treatment schedule.
Arrow marks start of abrocitinib treatment. Study: Spatial proteomics identifies JAKi as treatment for a lethal skin disease In a recent study published in the journal Nature , researchers tested Janus kinase inhibitors (JAKi) as potential treatments for drug-induced skin reactions, including toxic epidermal necrolysis (TEN), using deep visual proteomics (DVP) to analyze skin biopsies from patients. They identified them as key drivers of TEN (JAK/STAT [signal transducers and activators of transcription] and interferon signaling pathways) and showed that JAKi reduced disease severity and promoted recovery in both mouse models and human patients.
Background TEN patients often suffer from complications like.